Despite already being embroiled in a back and forth with the British government over the price of its cystic fibrosis drugs, Vertex Pharmaceuticals appears prepared to keep the feud alive with its latest move.
The drugmaker, according to a STAT report, has opted not to provide the government with information about its latest drug to a cost-effectiveness watchdog, effectively delaying the approval-to-market pipeline.
Vertex and the British government have been involved in a steady battle over its cystic fibrosis treatments for more than two years.
Click here to read the full report. (Paid subscription required)